ArticleEmerging infectious diseases2013
Characteristics of group A Streptococcus strains circulating during scarlet fever epidemic, Beijing, China, 2011.
Article in Emerging infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Pooled it
- Tracing the recent evolution of Group AEmerging microbes & infections · 2026Review
- Scarlet fever and meteorological exposures in Jiangsu, China: a time-stratified case-crossover study.BMC public health · 2025Article
- Ongoing epidemic of scarlet fever in Shanghai and the emergence of M1The Lancet regional health. Western Pacific · 2025Article
- The intricate pathogenicity of Group AVirulence · 2024Review
- Clinical Snapshot of Group A Streptococcal Isolates from an Australian Tertiary Hospital.Pathogens (Basel, Switzerland) · 2024Article
- A Review ofPathogens (Basel, Switzerland) · 2021Review
- Identification of epidemic scarlet fever group AAccess microbiology · 2021Article
- Prophage exotoxins enhance colonization fitness in epidemic scarlet fever-causing Streptococcus pyogenes.Nature communications · 2020Article
- Incidence of Scarlet Fever in Children in Jeju Province, Korea, 2002-2016: An Age-period-cohort Analysis.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2019Article
- Resurgence of scarlet fever in China: a 13-year population-based surveillance study.The Lancet. Infectious diseases · 2018Observational
- Defining Host Responses during Systemic Bacterial Infection through Construction of a Murine Organ Proteome Atlas.Cell systems · 2018Article
- Scarlet Fever Epidemic in China Caused by Streptococcus pyogenes Serotype M12: Epidemiologic and Molecular Analysis.EBioMedicine · 2018Article
- Identification and Characterization of Fluoroquinolone Non-susceptibleFrontiers in microbiology · 2018Article
- Spatiotemporal epidemiology of scarlet fever in Jiangsu Province, China, 2005-2015.BMC infectious diseases · 2017Article
- Incidence and Characteristics of Scarlet Fever, South Korea, 2008-2015.Emerging infectious diseases · 2017Article
- AnFrontiers in microbiology · 2017Article
- High Prevalence of Macrolide-resistance and Molecular Characterization ofFrontiers in microbiology · 2017Article
- The Association between Environmental Factors and Scarlet Fever Incidence in Beijing Region: Using GIS and Spatial Regression Models.International journal of environmental research and public health · 2016Article
- Estimated burden of group a streptococcal pharyngitis among children in Beijing, China.BMC infectious diseases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Scarlet fever is one of a variety of diseases caused by group A Streptococcus (GAS). During 2011, a scarlet fever epidemic characterized by peak monthly incidence rates 2.9-6.7 times higher than those in 2006-2010 occurred in Beijing, China. During the epidemic, hospital-based enhanced surveillance for scarlet fever and pharyngitis was conducted to determine characteristics of circulating GAS strains. The surveillance identified 3,359 clinical cases of scarlet fever or pharyngitis. GAS was isolated from 647 of the patients; 76.4% of the strains were type emm12, and 17.1% were emm1. Almost all isolates harbored superantigens speC and ssa. All isolates were susceptible to penicillin, and resistance rates were 96.1% to erythromycin, 93.7% to tetracycline, and 79.4% to clindamycin. Because emm12 type GAS is not the predominant type in other countries, wider surveillance for the possible spread of emm12 type GAS from China to other countries is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.